Newstral
Article
Dallas News on 2023-05-11 13:05
Plano’s Reata Pharmaceuticals halts chronic kidney disease drug development
Related news
- Plano’s Reata Pharmaceuticals strikes a $7.3 billion deal with biotech giant BiogenDallas News
- Reata Pharmaceuticals sets terms for initial public offeringbizjournals.com
- Reata Pharmaceuticals surges more than 23 percent in stock debutbizjournals.com
- Reata Pharmaceuticals will move HQ into new Plano high-riseDallas News
- Reata Announces Clinical Trial Design for FALCON, a Phase 3 Trial of Bardoxolone Methyl for the Treatment of Autosomal Dominant Polycystic Kidney Diseasecapitolhilltimes.com
- New Plano tower built for Reata Pharmaceuticals is back on the market againDallas News
- MBiogen agrees to acquire Reata Pharmaceuticals for $7.3 billion to boost its rare-disease offering2 min readmarketwatch.com
- Ozempic cuts risk of chronic kidney disease complications, study findsThe New York Times
- Metyos raises €2.3 pre-seed to combat chronic kidney diseasetech.eu
- PFDA approves Amgen’s Parsabiv drug to treat chronic kidney diseasepacbiztimes.com
- Startup building ‘biowearables’ for chronic kidney disease nets €2.3Mthenextweb.com
- MStocks in focus: Reata Pharmaceuticals stock soars after FDA-drug approval; Novavax falls after vaccine maker issues ‘substantial doubts’ over future operations2 min readmarketwatch.com
- Reata stock soars on FDA approval for ultra-rare disease drug after 15 yearsDallas News
- SFDA approves drug for cats with chronic kidney disease, giving pet owners hopesilive.com
- IHere’s why Reata Pharmaceuticals gained 20% on Wednesdayinvezz.com
- Chronic kidney disease bill introducedjournalrecord.com
- Overdiagnosis of chronic kidney diseasevillages-news.com
- MReata Pharma kidney drug meets study goals, stock haltedmarketwatch.com
- Hospital temporarily halts kidney tra...expressandstar.com